GoCART

Springer eBooks, pp. 221–224

Abstract

Abstract Cellular therapies manufactured from cells of haematopoietic origin, such as CAR-T–cell therapies, provide a revolutionary treatment for patients suffering from haematological diseases. Nonetheless, there are considerable challenges in the implementation of these therapies in this rapidly evolving field. These challenges include but are not limited to the complexity of the supply chains for these living drugs and the management of side effects, requiring centre qualification as well as additional and ongoing education of health care professionals; the long-term follow-up of patients treated with therapies with curative intent; the myriad regulatory requirements at the European Union and local level; and reimbursement of the treatments by budget-constrained authorities.

Authors 4

1. Sofie Rosanne Terwel corresponding Aachen EBMT GoCART

   European Society for Blood and Marrow Transplantation

   Affiliation as printed

   EBMT GoCART, Leiden, The Netherlands

2. Jurgen H. E. Kuball Aachen Legal Regulatory Affairs Committee (LRAC) of EBMT

   Utrecht University · University Medical Center Utrecht · European Society for Blood and Marrow Transplantation

   Affiliation as printed

   Department of Hematology, and Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands

   Legal Regulatory Affairs Committee (LRAC) of EBMT, Barcelona, Spain

3. Martin Dreyling

   Ludwig-Maximilians-Universität München

   Affiliation as printed

   Department of Medicine III, Ludwig Maximilians University Munich, Munich, Germany

4. Francesco Cerisoli

   European Hematology Association

   Affiliation as printed

   EHA, The Hague, The Netherlands